A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Non-alcoholic Steatohepatitis Clinical Trial

Official title:

A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05945537
• Other study ID #: INI-822-001
• Status: Recruiting
• Phase: Phase 1
• Start date: September 8, 2023
• Est. completion date: July 28, 2024

Study information

• Verified date: March 2024
• Source: Inipharm Australia Pty Ltd
• Contact: Katelyn Patterson
• Phone: +1 209-402-1568
• Email: kpatterson[@]inipharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers in Parts A and B and in participants with a history of NASH or presumed NASH in Part C.

Description:

The study will consist of 3 parts: Approximately 96 participants are planned to be enroled into the study. - In Part A (SAD), approximately 48 healthy adult participants are planned to be enroled in 6 cohorts of 8 participants each (Cohorts A1 to A6, including one fasted:fed crossover cohort to assess food effect). - In Part B (MAD), approximately 24 healthy adult participants are planned to be enroled in 3 cohorts of 8 participants each (Cohorts B1 to B3). - In Part C (Pharmacodynamics), approximately 24 participants with NASH or presumed NASH are planned to be enroled in 2 cohorts of 12 participants each (Cohorts C1 to C2).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: July 28, 2024
• Est. primary completion date: May 20, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. 18 to 55 years of age (inclusive at the time of informed consent).

2. Clinical laboratory values within normal range at Screening and Day -1, as specified by the testing laboratory, unless deemed not clinically significant by the Investigator or designee.

3. Females must not be pregnant or lactating, and must use acceptable, highly effective double contraception from Screening until 90 days after their last dose of IP or 5 half-lives, whichever is longer. Females must not donate ova from the first dose of IP until at least 90 days after the last dose of IP or 5 half-lives, whichever is longer.

4. Males must be surgically sterile (> 30 days since vasectomy [documented evidence] with no viable sperm), or, if engaged in sexual relations with a WOCBP, they must use a condom and either his partner must be surgically sterile (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), or an acceptable, highly effective contraceptive method must be used from Day -1 until study completion. Males must not donate sperm from the first dose of IP until at least 90 days after the last dose of IP or 5 half-lives, whichever is longer.

5. Able and willing to attend the necessary visits to the study site.

6. Able and willing to refrain from use of tobacco and other nicotine-containing products while at the study site.

7. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.

8. Normal renal function (estimated glomerular filtration rate > 60 mL/min using Cockcroft-Gault).

For Parts A and B only:

9. In good general health, with no significant medical history, and no clinically significant abnormalities on physical examination at Screening and/or before the first administration of IP, at the discretion of the Investigator or designee.

10. Body mass index (BMI) = 18.0 and = 30.0 kg/m2 with a maximum body weight of 120 kg.

For Part C only:

11. A diagnosis of NASH confirmed by 1 or more of the following:

1. Historical liver biopsy consistent with NASH (presence of Grade 1 steatosis, hepatocellular ballooning, and lobular inflammation) according to the NAFLD activity score.

2. F0-3 fibrosis according to the NASH Clinical Research Network classification within 1 year of Screening.

3. A clinical diagnosis of NASH.

4. FibroScan-aspartate aminotransferase (FAST) score > 0.35.

12. ALT > 1.5 × ULN at 2 separate time points in the past 6 months. At least 1 time point must be at Screening and the values must be at least 2 weeks apart.

13. Fibrosis-4 (FIB-4) score = 2.67, controlled attenuation parameter (CAP) score by FibroScan® = 280 dB/m, and liver stiffness measurement (LSM) by FibroScan® = 14 kPa.

14. No documented weight loss > 5% in the 6 months preceding Screening.

15. If on glucagon-like peptide 1 (GLP1) agonists, sodium-glucose co-transporter 2 (SGLT2) inhibitors, or vitamin E (dose > 400 IU/day), then should have been on a stable dose for at least 3 months.

16. Platelet count > 150,000 and albumin > 3.5 mg/dL.

17. BMI = 18.0 and = 40.0 kg/m2.

Exclusion Criteria:

1. Underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely for the participant to comply with the protocol or complete the study per protocol.

2. Blood donation or significant blood loss (> 500 mL) within 60 days prior to the first administration of IP.

3. Plasma donation within 7 days prior to the first administration of IP.

4. Fever (body temperature > 37.7°C) or symptomatic viral or bacterial infection within 2 weeks prior to Day 1.

5. Dysphagia that would limit ability to swallow IP.

6. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.

7. Abnormalities in physical examination at Screening and Day -1 which are deemed clinically significant by the Investigator or designee.

8. Abnormal electrocardiogram (ECG) measurements (an average of 3 readings) at Screening and Day -1 that are considered by the Investigator or designee to be clinically significant, including corrected QT interval with Fridericia's correction (QTcF) > 450 msec (males) or > 470 msec (females).

9. Unstable vital sign(s) or the following values seen at Screening or prior to dosing following 5 minutes of resting in the semi-supine position (an abnormal value may be

repeated once, separated by at least 5 minutes, with both values documented):

1. Systolic blood pressure < 90 mmHg or > 160 mmHg OR

2. Diastolic blood pressure < 50 mmHg or > 95 mmHg OR

3. Pulse rate < 45 beats per minute (bpm) or > 100 bpm.

10. History or presence of other causes of liver disease including genetic, autoimmune, viral, and alcoholic liver disease.

11. Cirrhosis of the liver as defined by:

1. A prior history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding OR

2. F4 on previous liver biopsy OR

3. Historical evidence of cirrhosis on liver imaging.

12. History of hospitalisation or major surgery within 6 months prior to Screening.

13. Infections requiring parenteral antibiotics within 6 months prior to Screening.

14. Vaccination with a live vaccine within 4 weeks prior to the first administration of IP.

15. Exposure to any significantly immune suppressing drug (including experimental therapies as part of a clinical study) within 4 months prior to Screening or 5-half-lives, whichever is longer.

16. Positive blood screen for active infections including human immunodeficiency virus (HIV), hepatitis B virus (HBV)or hepatitis C virus (HCV) at Screening.

17. Positive toxicology screening panel (urine test including Methamphetamine, Opiates, Cocaine, tetrahydrocannabinol, Phencyclidine, Benzodiazepines, Barbiturates, Methadone, tricyclic antidepressants and Amphetamine), or alcohol breath test at Screening or Day -1.

18. History of substance abuse or dependency or history of recreational intravenous drug use over the last 12 months (by self-declaration).

19. History of alcohol use disorder (within 9 months prior to Screening by self-declaration) or consumption of significant amounts of alcohol (by self-declaration), defined as > 10 standard drinks per week or > 4 standard drinks on any single day (where 1 standard drink = 360 mL of beer, 45 mL of 40% spirit, or a 150 mL glass of wine). Participants who are unable to abstain from alcohol 72 hours prior to Screening and Day -1 visits and until study completion are to be excluded.

20. Use of any IP or investigational medical device within 30 days for small molecules (or 5 half-lives of the IP if longer than 30 days) or 90 days for biologics prior to first IP administration.

21. Anything that the Investigator considers would jeopardise the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.

22. Bariatric surgery.

23. Cardiovascular disease including heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, or any other cardiovascular illness that, in the opinion of the Investigator, warrants exclusion from the study.

For Parts A and B only:

24. Use of (or anticipated use of) any prescription drugs (other than hormonal contraception; oral contraceptive pills [OCPs], long-acting implantable hormones, injectable hormones, or an intrauterine device [IUD]), any known drugs or supplements that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes, over-the-counter (OTC) medication, herbal remedies, supplements or vitamins within 48 hours of IP administration and during the course of the study without prior approval of the Investigator and independent MM. Simple analgesia (paracetamol < 2 g/day) may be permitted at the discretion of the Investigator.

25. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, haematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity, as determined by the Investigator.

26. History of or suspected malignancy. Participants with basal or squamous cell carcinoma of the skin or carcinoma in situ that has been successfully treated could be included at the discretion of the Investigator or designee.

For Part C only:

27. ALT = 5 × ULN.

28. Use of (or anticipated use of) any known drugs or supplements that are moderate or strong inhibitors/inducers of CYP enzymes or any drugs that are substrates of CYP2C9 with narrow therapeutic index or any drugs that are metabolised by CYP3A4 during the course of the study. Prescription medications for stable medical condition may be allowable if the Investigator considers they will not interfere with the study; the independent MM may be contacted to discuss any particular medications.

29. Participants with uncontrolled medical conditions. Participants may be included if they have a stable medical condition (stable for at least 3 months with no change in medication) which is not deemed by the Investigator to interfere with the study; the independent MM may be contacted for discussion.

30. History of significant cardiovascular disease, including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischaemic attack within 6 months prior to the first dose of IP.

31. Uncontrolled diabetes mellitus (haemoglobin A1c [HbA1c] > 8.5% at Screening).

32. Malignancy within the last 5 years; basal or squamous cell carcinoma of the skin or carcinoma in situ that has been successfully treated could be included at the discretion of Investigator or designee.

33. History or presence of a condition associated with significant immunosuppression.

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Intervention

Drug:
• INI-822 (A)
Different dose levels of INI-822

Other:
• Placebo (B)
Matching placebo to INI-822

Locations

Country	Name	City	State
Australia	CMAX Clinical Research	Adelaide	South Australia

Sponsors (1)

Lead Sponsor	Collaborator
Inipharm Australia Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs).	AEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Part A: Up to 5 Weeks
Primary	Incidence of adverse events (AEs).	AEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Part A fasted fed crossover cohort: Up to 8 weeks
Primary	Incidence of adverse events (AEs).	AEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Part B: Up to 7 weeks
Primary	Incidence of adverse events (AEs).	AEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Part C: Up to 9 weeks
Primary	Number of participants with clinical laboratory abnormalities		Part A: Up to 5 Weeks
Primary	Number of participants with clinical laboratory abnormalities		Part A fasted fed crossover cohort: Up to 8 weeks
Primary	Number of participants with clinical laboratory abnormalities		Part B: Up to 7 weeks
Primary	Number of participants with clinical laboratory abnormalities		Part C: Up to 9 weeks
Secondary	Plasma area under the curve (AUC) from time 0 to t (AUC0-t)		Part A: Up to 5 Weeks, Part A fasted fed crossover cohort: Up to 8 weeks, Part B: Up to 7 weeks, Part C: Up to 9 weeks
Secondary	AUC from time 0 to infinity (AUC0-inf)		Part A: Up to 5 Weeks, Part A fasted fed crossover cohort: Up to 8 weeks, Part B: Up to 7 weeks, Part C: Up to 9 weeks
Secondary	Maximum concentration (Cmax)		Part A: Up to 5 Weeks, Part A fasted fed crossover cohort: Up to 8 weeks, Part B: Up to 7 weeks, Part C: Up to 9 weeks